Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. A novel murine model for sporadic, malignant peripheral nerve sheath tumors, driven by BrafV600E and Pten loss.Disease models & mechanisms · 2025
   Article
2. Case Report: Malignant peripheral nerve sheath tumor of the thoracic spine with postoperative recurrence and intracranial metastasis-a review of the literature.Frontiers in oncology · 2025
   Article
3. Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities.Molecular oncology · 2024
   Article
4. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state.Acta neuropathologica · 2021
   Article
5. Circulating tumor DNA for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.Journal of neuro-oncology · 2021
   Review
6. Toward Understanding the Mechanisms of Malignant Peripheral Nerve Sheath Tumor Development.International journal of molecular sciences · 2021
   Review
7. The rare primary bone sarcomas: imaging-pathological correlation.Skeletal radiology · 2021
   Review
8. Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor.NPJ precision oncology · 2021
   Article
9. Genetics of human malignant peripheral nerve sheath tumors.Neuro-oncology advances · 2020
   Review
10. Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.Neuro-oncology advances · 2020
    Article
11. Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives.Neuro-oncology advances · 2020
    Review
12. Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies.PLoS genetics · 2019
    Article
13. Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.Current treatment options in oncology · 2019
    Review
14. Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities.The Journal of pathology · 2018
    Review
15. Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017
    Article
16. Histopathologic findings in malignant peripheral nerve sheath tumor predict response to radiotherapy and overall survival.Neuro-oncology advances
    Article

Corrections and comments

• Erratum for
  Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.2016

Authors and funding

14 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.